Rhythm Pharmaceuticals/$RYTM

Rhythm Pharmaceuticals stock falls after reporting Q3 EPS of -$0.82, missing the consensus estimate of -$0.73.
14 hours agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Ticker

$RYTM
Sector
Health
Primary listing
NASDAQ

Employees

283
Headquarters
Boston, United States
Website
rhythmtx.com

RYTM Metrics

BasicAdvanced
$7B
-
-$3.11
-
-

What the Analysts think about RYTM

Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.

Bulls say / Bears say

Global net product revenue for IMCIVREE reached $48.5 million in Q2 2025, up 29% sequentially and 67% year-over-year, driven primarily by Bardet-Biedl syndrome prescriptions (GlobeNewswire).
The Phase 2 trial of oral MC4R agonist bivamelagon met its primary endpoint with statistically significant, clinically meaningful BMI reductions, validating Rhythm’s pipeline diversification beyond setmelanotide (GlobeNewswire).
In February 2025, the FDA approved an expanded IMCIVREE label to include pediatric patients aged 2 years and older, increasing the addressable market for rare genetic obesity disorders (GlobeNewswire)
The quarter’s net loss widened to $48 million, up from $33.6 million a year earlier, underscoring rising cash burn from advancing clinical programs (TipRanks).
The FDA has set a PDUFA goal date of December 20, 2025 for Rhythm’s supplemental NDA in acquired hypothalamic obesity, and any delay or negative outcome could stall expansion into a larger patient population (GlobeNewswire).
Major pharma players like Roche have committed up to $5.3 billion to develop competing obesity drugs, intensifying market competition and potentially limiting IMCIVREE’s uptake (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.

RYTM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RYTM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

RYTM News

AllArticlesVideos
Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points

Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points

Investors Business Daily1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RYTM

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs